Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality.

European urology focus·2025

Same author

Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.

European urology oncology·2025

Same author

Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer.

European urology oncology·2025

Same author

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

European urology·2025

Same author

Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.

The oncologist·2025

Same author

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

European urology·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Strategies for optimizing bacillus Calmette-Guérin.

Jay B Shah¹, Ashish M Kamat

¹Department of Urology, MD Anderson Cancer Center, Houston, TX 77030, USA.

The Urologic Clinics of North America

|April 2, 2013

Summary

Intravesical Bacillus Calmette-Guérin (BCG) is crucial for high-risk superficial bladder cancer. Optimizing patient selection and administration techniques is essential for maximizing treatment effectiveness and managing challenges associated with BCG therapy.

More Related Videos

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: May 12, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System

Published on: January 31, 2018

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Area of Science:

Urology
Oncology

Background:

Intravesical Bacillus Calmette-Guérin (BCG) is a cornerstone therapy for superficial bladder cancer with moderate-to-high risk of recurrence or progression.
Despite its efficacy, BCG treatment presents unique challenges that necessitate careful management.

Purpose of the Study:

To review the historical role of BCG in bladder cancer management.
To discuss strategies for optimizing BCG therapy, focusing on patient selection and technical administration.

Main Methods:

Literature review of BCG's role in bladder cancer over several decades.
Analysis of selection criteria and technical approaches for BCG administration.

Main Results:

BCG has significantly impacted bladder cancer treatment outcomes.
Specific patient selection and precise technical application are key to optimizing BCG efficacy.

Conclusions:

Effective use of intravesical BCG requires a thorough understanding of its application.
Optimizing patient selection and administration techniques is critical for achieving the best outcomes in superficial bladder cancer management.